Fortunately, sorafenib and regorafenib inhibit the expression of ADAM9 mRNA [23,24], restoring the host immunity against HCC and generating a room for synergistic action by adoptive cell therapy with NK cells or CD8+ T cells. Here, ADAM9 is linked to hepatocellular carcinoma.